Back to Search

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Protocol Number: 201806120
  • Principal Investigator: Kuroki, Lindsay
  • Cancer Types: Gynecologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions